参考文献/References:
［1］ZHUB-P Z, ROLFS R T, NangleBE, et al Effect of the interval between pregnancies on perinatal outcomes ［J］. New England Journal of Medicine, 1999, 340 (8): 589–594.
［2］RODRIGUEZ M, CHANG R，Thiel De bocanegra H，et al. The impact of postpartum contraception on reducing preterm birth:findings from California ［J］.Am J ObstetGynecol, 2015, 213 (703): e1–e6.
［3］Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review ［J］. ObstetGynecol，2011，117（3）:657-662.
［4］Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical eligibility criteria for contraceptive use, 2016 ［J］. MMWR Recomm Rep，2016，65（3）:1-104.
［5］Gray RH, Campbell OM, Apelo R, et al. Risk of ovulation during lactation ［J］. Lancet 1990，335（8680）:25-29.
［6］TRUSSELL J. Contraceptive failure in the United States ［J］. Contraception, 2004, 70 (2): 89-96.
［7］Hatcher RA, Trussel RA, Nelson AL, et al. Contraceptive Technology ［M］.20th ed, Ardent edia, New York,2011.
［8］Cohen R, Sheeder J, Arango N, et al. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices ［J］. Contraception,2016，93（2）:178-183.
［9］AIKEN A R, CREININ M D, KAUNITZ A M, et al. Global fee prohibits postpartum provision of the most effective reversible contraceptives ［J］. Contraception, 2014, 90 (5): 466-467.
［10］American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice. Committee Opinion No. 670: Immediate Postpartum Long-Acting Reversible Contraception ［J］ . Obstet Gynecol,2016，128(2):e32-e37.
［11］World Health Organization. Medical eligibility criteria for contraceptive use ［M］.5th ed,Geneva,2015.
［12］Nexplanon. US Food and Drug Administration (FDA) approved product information. Revised March 14, 2016. US National Library of Medicine.
［13］Park J, Robinson N, Wessels U, et al. Progestin-based contraceptive on the same day as medical abortion ［J］. Int J GynaecolObstet，2016，133（2）:217-220.
［14］OGBURN J A, ESPEY E, STONEHOCKER J. Barriers to intrauterine device insertion in postpartum women ［J］. Contraception, 2005, 72 (6): 426-429.
［15］Welkovic S, LOBF Costa, Faúndes A, et al. Postpartum bleeding and infection after post- placental IUD insertion ［J］. Contraception. 2001，63（3）: 155-158.
［16］World Health Organization. Medical eligibility criteria for contraceptive use ［Z］, 2014.
［17］Centers for Disease Control, Prevention. CDC ［Z］, 2014.
［18］Zerden ML, Stuart GS, Charm S, et al. Two-week postpartum intrauterine contraception insertion: a study of feasibility, patient acceptability and short-term outcomes ［J］. Contraception，2017，95（1）:65-70.
［19］Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review ［J］. Contraception，2009，80（4）:327-336.
［20］Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up ［J］. Contraception，2003，68（1）:31.
［21］Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systemic review ［J］. Contraception，2009，80（4）:327–336.
［22］GRIMES D A, LOPEZ L M, SCHULZ K F, et al. Immediate post-partum insertion of intrauterine devices ［J］. Cochrane Database of Systematic Reviews, 2010 (5): CD003036.
［23］Heinemann K, Reed S, Moehner S, et al.Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: The European active surveillance study for intrauterine devices ［J］.Contraception,2015，91(4):280-283.
［24］Heinemann K, Reed S, Moehner S，et al.Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices ［J］. Contraception，2015，91 (4):274.
［25］Chi IC, Wilkens L, Rogers S. Expulsions in immediate postpartum insertions of Lippes Loop D and Copper T IUDs and their counter-part Delta devices—An epidemiological analysis ［J］.Contraception，1985，32（2）:119–134.
［26］COHEN R, SHEEDER J, ARANGO N, et al. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices ［J］. Contraception, 2016, 93 (2): 178-183.
［27］LEVI E E, STUART G S, ZERDEN M L, et al. Intrauterine device placement during cesarean delivery and continued use 6 months postpartum a randomized controlled trial ［J］. Obstetrics and Gynecology, 2015, 126 (1): 5-11.
［28］CHEN B A, REEVES M F, HAYES J L, et al. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery a randomized controlled trial ［J］. Obstetrics and Gynecology, 2010, 116 (5): 1079-1087.
［29］BIRGISSON N E, ZHAO Qiu-hong, SECURA G M, et al. Preventing unintended pregnancy: the contraceptive choice project in review ［J］. Journal of Women's Health, 2015, 24 (5): 349-353.
［30］Heinemann K, Westhoff CL, Grimes DA, et al. Intrauterine devices and the risk of uterine perfo- rations: final results from the EURAS-IUD study ［J］. Obstet Gynecol， 2014，123 (suppl 1):3S.
［31］Phillips SJ, Tepper NK, Kapp N, et al. Progestogen-only contraceptive use among breastfeeding women: a systematic review ［J］. Contraception，2016，94（3）:226-252.
［32］World Health Organization Task Force for Epidemiological Research on Reproductive Health,Special Programme of Research,Development and Research Training in Human Reproduction.Progestogen-only Contraceptives During Lactation:I.InfantGrowth［J］.Contraception，1994，50（1）：35-53．
［33］KAPP N, CURTIS K, NANDA K. Progestogen-only contraceptive use among breastfeeding women: a systematic review ［J］. Contraception, 2010, 82 (1): 17-37.
［34］Brito M B, Ferriani R A, Quintana S M, et al. Safety of the Etonogestrel-releasing Implant During the Immediate Postpartum Period:a Pilot Study ［J］.Contraception, 2009, 80 (6): 519-526.
相似文献/References:
[1]陈诚,常青.瘢痕子宫剖宫产围手术期处理[J].中国计划生育和妇产科,2012,(04):0.
CHEN Cheng,CHANG Qing*.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(1):0.
[2]李力,韩磊.产后避孕的昨天、今天与未来[J].中国计划生育和妇产科,2012,(06):0.
LI Li,HAN Lei PLA Family Planning Technique Center,Daping Hospital of The Third Military Medical University,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(1):0.
[3]吴尚纯,楚光华.产后避孕的国内外指南[J].中国计划生育和妇产科,2012,(06):0.
WU Shang-chun,CHU Guang-hua ..[J].Chinese Journal of Family Planning & Gynecotokology,2012,(1):0.
[4]金力.产后避孕的必要性及知情选择[J].中国计划生育和妇产科,2012,(06):0.
JIN Li.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(1):0.
[5]熊薇,刘兴会.从产科视角看产后避孕[J].中国计划生育和妇产科,2012,(06):0.
XIONG Wei,LIU Xing-hui* West China Second Hospital,Sichuan University,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(1):0.
[6]柳宛璐,吴媛媛,乔福元,等.分娩方式与产后避孕[J].中国计划生育和妇产科,2012,(06):0.
LIU Wan-lu,WU Yuan-yuan,QIAO Fu-yuan* Deptment of Obstetrics and Gynecology,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(1):0.
[7]刘欣燕.产后避孕的严峻现状和新挑战[J].中国计划生育和妇产科,2019,(1):3.
[8]周倩,彭萍,刘欣燕*.产后避孕与女性生育力保护[J].中国计划生育和妇产科,2019,(1):5.
[9]胡惠英,马骁,李春颖*,等.产后口服避孕药的正确选择[J].中国计划生育和妇产科,2019,(1):11.
[10]陈蔚琳,吕昌帅,刘欣燕*.产后避孕认识的误区及对策[J].中国计划生育和妇产科,2019,(1):15.